Posts tagged ‘Glioblastoma’
March 5th, 2011
Both brainstem gliomas and glioblastomas have poor prognosis, which raises the importance of translational medical research that could lead to new targeted therapies.
Research by Phillips et al, has shown that Akt and Notch signaling are hallmarks of poor prognosis, suggesting that identification of molecular subtypes may be useful in the development of new therapies.
February 22nd, 2011
Today on Pharma Strategy Blog, Sally Church provides further insight into glioblastoma multiforme (GBM), the most common and deadly form of brain cancer.
Recent research has highlighted the role that encoding nuclear factor of κ-light polypeptide gene enhancer in B-cells inhibitor-α (NFKBIA) has on tumors and patient survival.
Sally analyzes the significance of this for those in the pharma/biotech industry looking to bring new products to market.
January 3rd, 2011
Published by Sally Church on Pharma Strategy Blog